These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30922578)

  • 1. Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
    Qin J; Wang J; Lin X; Wang J; Xiong Z; Wang R; Zhao H; Kong X
    J Thorac Oncol; 2019 Apr; 14(4):e65-e68. PubMed ID: 30922578
    [No Abstract]   [Full Text] [Related]  

  • 2. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
    BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
    Yamamoto N; Goto K; Nishio M; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Tajima K; Tamura T
    Int J Clin Oncol; 2017 Feb; 22(1):70-78. PubMed ID: 27659294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
    Forde PM; Ettinger DS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):528-32. PubMed ID: 26351816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
    Redig AJ; Costa DB; Taibi M; Boucher D; Johnson BE; Jänne PA; Jackman DM
    JAMA Oncol; 2016 Sep; 2(9):1240-2. PubMed ID: 27387964
    [No Abstract]   [Full Text] [Related]  

  • 8. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
    Wang DD; Ma L; Wong MP; Lee VH; Yan H
    PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
    López-Ayllón BD; de Castro-Carpeño J; Rodriguez C; Pernía O; Ibañez de Cáceres I; Belda-Iniesta C; Perona R; Sastre L
    Int J Clin Exp Pathol; 2015; 8(3):2888-98. PubMed ID: 26045797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.
    Zhou H; Xiang Q; Hu C; Zhang J; Zhang Q; Zhang R
    Hereditas; 2020 Jul; 157(1):32. PubMed ID: 32703314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
    Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
    Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
    [No Abstract]   [Full Text] [Related]  

  • 14. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
    Zhou Q; Yang JJ; Chen ZH; Zhang XC; Yan HH; Xu CR; Su J; Chen HJ; Tu HY; Zhong WZ; Yang XN; Wu YL
    J Hematol Oncol; 2016 Sep; 9(1):86. PubMed ID: 27619632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.
    Lozano MD; Labiano T; Zudaire I; Subtil JC; Gúrpide A; Echeveste JI; Zulueta JJ; Martín-Algarra S; Pérez-Gracia JL
    Int J Surg Pathol; 2015 Apr; 23(2):111-5. PubMed ID: 24942894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
    Kim S; Park AK; Cho J
    Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
    Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
    Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
    Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
    Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
    Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
    Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.